tbuckley/cabot-search huggingface dataset:
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Authors: Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Susan O'Brien, Jan A. Burger
Journal: Clinical Cancer Research (2016)

Abstract Background: Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients with del17p or with TP53 mutations. Ibrutinib is broadly indicated for the treatment of patients with CLL and specifically including those with 17p deletion. The optimal use of ibrutinib in combination with other agents remains controversial. Experimental Design: We report the long-term outcome [median follow-up of 47 months (range, 36–51 months)] of 40 patients with high-risk CLL, treated on the first ibrutinib combination trial with rituximab (IR). The majority of patients (36/40) were previously treated. Results: Median age was 65 years, and 21 patients (52%) had 17p deletion. Median duration on treatment was 41 months (range, 2–51 months), and median number of treatment cycles was 42 (range, 2–49). Overall response rate was 95%, and 9 patients (23%) attained a complete remission. Twenty-one patients discontinued treatment, 10 due to disease progression, 9 for other causes, and 2 due to stem cell transplantation; the remaining 19 patients continue on ibrutinib. Median progression-free survival for all patients was 45 months, which was significantly shorter in the subgroup of patients with del17p (n = 21, 32.3 months, P = 0.02). Fourteen patients (35%) died, five from progressive disease, five from infections, and four from other causes. Median overall survival has not been reached. Conclusions: IR combination therapy leads to durable remissions in high-risk CLL; the possible benefit from the addition of rituximab is currently explored in a randomized trial. Clin Cancer Res; 23(9); 2154–8. ©2016 AACR.
Treatment of Iron Overload in Transfusion-Dependent Anemias Post Hematopoietic Stem Cell Transplantation: When to Start? When to Stop?
Authors: Andrea Jarisch, Regine Grosse, Emilia Salzmann-Manrique, Roland Fischer, Jan Soerensen, Renate Hammerstingl, Eva Rettinger, Andre Manfred Willasch, Thomas Klingebiel, Peter Bader
Journal: Blood (2015)
Non-Myeloablative Conditioning of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Protects Against Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (HCT) but Retains Anti-Tumor Activity.
Authors: Robert Lowsky, Tsuyoshi Takahashi, Yin Ping, Judith Shizuru, Robert S. Negrin, Samuel Strober
Journal: Blood (2004)
Impact of Prophylaxis with Aerosolized Amphotericin-B Deoxycholate (d-AmB) on Respiratory Tract Invasive Fungal Infections (IFIs) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Enrico Morello, Irene M. Cavattoni, Pietro Fabris, Silvia Coin, Barbara Amato, Vincenzo Cassibba, Marco Casini, Leonardo Pagani, Sergio Cortelazzo
Journal: Blood (2007)
Anticancer treatment and cognitive functions in elderly cancer patients: A prospective study
Authors: A. M. Minisini, P. Ermacora, S. Russo, G. Cardellino, C. Andreetta, R. Sottile, A. Piga, M. Balestrieri, F. Puglisi
Journal: Journal of Clinical Oncology (2006)

8543 Background: It has been reported that anticancer treatment may alterate cognitive functions in cancer patients but very few prospective studied addressed this issue. Moreover, little is known about the cognitive impact of anticancer treatment in elderly cancer patients. We aimed at investigating the effect on cognitive functions of antiblastic chemotherapy and endocrine therapy in a consecutive series of elderly cancer outpatients. Methods: We evaluated cognitive functions by means of the Cambridge Cognitive Examination (CAMCOG) test and the Mini-Mental Scale Examination (MMSE) at baseline (before anticancer systemic treatment), after 3 months and after 6 months in cancer patients aged more than 65 years. Mood disturbances such as anxiety and depression were also evaluated (Hospital Anxiety and Depression Scale); comprehensive geriatric assessment and blood tests were performed at each evaluation. Results: Sixty patients were enrolled, 15 patients received chemotherapy (group 1), 13 patients received endocrine therapy (group 2) and 32 patients had neither chemotherapy nor endocrine therapy (group 3, control). Fifty-eight (97%) patients had no evidence of disease at the time of assessment. Median age was 71.5, 73 and 71 years in group 1, 2 and 3, respectively. At baseline, median Activities of Daily Living (ADL) score, Instrumental Activity of Daily Living (IADL) score, number of comorbidities and concomitant medications were 6, 8, 5, 1 in group 1, and 6, 8, 3, 2 in group 2, and 6, 8, 4, 2 in group 3, respectively. Median hemoglobin value was 12.9, 12.8, 13.3 g/dl in group 1, 2 and 3 respectively. At baseline, no significant unbalance was evident among groups. There was a statistically significant correlation between ADL or IADL score and CAMCOG total score (Spearman test, rho=0.4, p&lt;0.05). Higher scolarity level was associated with higher CAMCOG total score. No deterioration of CAMCOG score was evident in group 1, 2 and 3 after 3 and 6 months (paired t-test p&gt;.05); the separate analyses for the different items in CAMCOG test did not evidence any deterioration in time in the 3 groups. No worsening was seen in MMSE. Conclusions: Our study showed that anticancer treatment is not associated with rapid cognitive deterioration in elderly cancer patients. No significant financial relationships to disclose.
Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC)
Authors: S. Kawabata, M. Oka, M. Fukuda, A. Kinoshita, M. Fukuda, S. Nagashima, Y. Nakamura, H. Nakano, H. Soda, S. Kohno
Journal: Journal of Clinical Oncology (2004)

7291 GEM and CBDCA are active agents with different antitumor mechanisms for NSCLC. We conducted phase I study of GEM and CBDCA as a first-line therapy in advanced NSCLC. The main purpose of this study is to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of this combination therapy. Patients and Methods: Patients (pts) with previously untreated advanced NSCLC (<75 years old, adequate organ functions and ECOG PS 0–1) received escalating GEM doses on days 1 and 8 with a fixed target AUC = 5 of CBDCA on day 1 at 21-day schedule. CBDCA dose was determined by the Calvert formula using GFR estimated by 24-hour urine collection for creatinine clearance. GEM dose was escalated from 800 mg/m2 to MTD by 100-mg/m2. If WBC <2000 or Plt =4 days, Plt <2 x 104 or platelet transfusion with thrombocytopenia, >=G3 nonhematologic toxicity and the cancel of GEM on day 8 (skip of day 8). Results: A total of 9 pts were enrolled in this study. The pts' characteristics were as follows: median age 63 (range 43–75) years old, male/female = 9/0, PS 0/1 = 2/7, stage IIIB/IV = 4/5. DLT was observed in 0/3 pts of GEM 800 mg/m2, and 2/3 of GEM 900 mg/m2. In detail, DLTs in GEM 900 mg/m2 were skip of day 8 and thrombocytopenia. Overall, G3/4 thrombocytopenia, G3/4 neutropenia, and G3/4 leukopenia occurred 67%, 56%, and 33%, respectively. No platelet transfusion was required, and nonhematologic toxicities were mild. One of nine pts showed objective responses (0 CR, 1 PR; response rate = 11%). Conclusion: The recommended dose of this combination therapy was GEM 800 mg/m2 and CBDCA AUC = 5. To confirm this recommended dose, the extension study is ongoing. No significant financial relationships to disclose.
A phase I study evaluating bronchial artery infusion (BAI) of gemcitabine in recurrent or progressive non-small cell lung cancer (NSCLC).
Authors: T. Jirakulaporn, A. Khatri, J. Fisher, C. A. Dietz, M. N. Kirstein, R. S. Andrade, A. Dudek, M. Maddaus, R. A. Kratzke, J. D'Cunha
Journal: Journal of Clinical Oncology (2010)

e13080 Background: BAI therapy in lung cancer is of interest due to several advantages over systemic chemotherapy, including delivery of a large dose of drug directly to the tumor and less systemic toxicities. Methods: Patients with recurrent or progressive NSCLC following at least 2 lines of therapy were enrolled in a phase I study evaluating BAI of gemcitabine to assess safety, pharmacokinetics and local tumor response. Patients were given BAI of gemcitabine with a dose of 600 mg/m2 on day 1 of cycle 1, followed by intravenous gemcitabine of 1,000 mg/m2 on day 8 of cycle 1 and days 1 and 8 of all subsequent cycles. Each cycle lasted 21 days. Optional gemcitabine by BAI rather than IV on day 1 of odd numbered cycles was offered. Treatment was continued until progressive disease (PD) or toxicity. Pharmacokinetics for plasma gemcitabine, dFdU, and active triphosphorylated metabolite (dFdCTP) in peripheral blood mononuclear cells were evaluated following BAI and IV infusions. Results: A total of 4 patients were recruited. One patient was discontinued after inability to cannulate the bronchial artery. Three patients, all males, were treated according to the protocol. A total of 4 BAI therapies were performed with one patient receiving an additional BAI on day 1, cycle 5. Number of treatment cycles before PD was 4, 4, and 6. One patient achieved partial response after cycle 3, and 2 patients obtained stable disease. Toxicities were all grade ≤ 2 including nausea, vomiting, rigor, thrombocytopenia, and anemia. No grade 3 or 4 toxicity reported. Following intravenous administration, mean (±SD) AUCs for gemcitabine, dFdU, and dFdCTP were 19.1 ± 4.76, 1375 ± 722.1, and 591.3 ± 100.2 μM*hr, and following BAI, 9.88 ± 2.67, 889.9 ± 190.3, and 888.3 ± 743.2 μM*hr, respectively. Conclusions: BAI of gemcitabine is feasible and safe at initial dose of 600 mg/m2. A dose-escalating study should be completed to identify maximum tolerated dose and its efficacy. No significant financial relationships to disclose.
The Favorable Effect of Activating NOTCH1 Receptor Mutations On Long Term Outcome in T-ALL Is Treatment Related and Can Be Separated From NOTCH Pathway Activation by FBXW7 Loss of Function.
Authors: Corinne Kox, Martin Zimmermann, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Rolf Koehler, Svenja Leible, Gabriele Tolle, Obul Reddy Bandapalli, Stephen Breit, Martina Ulrike Muckenthaler, Andreas Kulozik
Journal: Blood (2009)
Primary clinical use of the sono-photo-dynamic therapy for advanced esophagocadiac and gastric adenocarcinoma.
Authors: Lucy Qing Li, Xiaohuai Wang, Iris Wenyin Zhang, Douglas Mitchell
Journal: Journal of Clinical Oncology (2014)

e15024 Background: Sonodynamic therapy (SDT), a procedure related with photodynamic therapy, is a promising new modality for treating deep-seated cancer. Two new chlorophyll derived sono-photo-sensitizing agents, along with ultrasound equipment for systemic treatment (SDT), have been developed by EEC Biotech and all approved by regulator for safety on human. Animal studies demonstrate that the sensitizers are specifically absorbed into tumor cells and SDT does inhibit growth of mouse S-180 sarcoma. An in vitro experiment with human breast and lung cancer cell-lines showed that SDT was strongly synergetic with chemotherapy. We reported before about using sono-photo-dynamic therapy (SPDT, a combination therapy of SDT and PDT ) as a supplementary or salvage treatment in advanced breast cancer, and now report some positive results in advanced esophageal and gastric cancer by using SPDT. Methods: Seven patients were pathologically proven advanced esophagocadiac and gastric adenocarcinoma. 3 patients had conventional chemotherapy before. With SPDT, Patients took the sensitizers sublingually on day 1 and 2; red light and multiple ultrasound transducers irradiate tumor area and whole body on day 4 to 6. The treatment was repeated. All patients had concurrent chemo with range from moderate to 1/2 conventional dosages selected to keep side effects at grade II or better. 2 patients received local radiation therapy as well. Results: The seven patients achieved CR 3(42.8%), PR 3 (42.8%), MR 1, with an overall response rate of 85%. The main SPDT side effects were easily reversible mild pain in tumor areas, tiredness and weakness. There was no skin sensitivity. SPDT/dose controlled chemo was well tolerated, even along with the radiation therapy. Conclusions: These preliminary data suggest that SPDT has almost no toxicity, but may dramatically enhance the conventional therapeutic efficacy in advanced refractory esophagocadiac and gastric adenocarcinoma. SPDT has a good trend to be a new systemic, low toxicity tumor therapy and merit for further investigation.
Glutathione-S-Transferase π Expression Helps for Differential Diagnosis between Mantle Cell Lymphoma and Marginal Zone Lymphoma with t(11;14).
Authors: D. Rolland, S. Gazzo, P. Felman, E. Callet-Bauchu, A. Traverse-Glehen, L. Baseggio, A. Paret, F. Chapuis, G. Salles, B. Coiffier, F. Berger, C. Thieblemont
Journal: Blood (2004)
CA 125 in the early detection of metastatic breast cancer
Authors: I. Ertl, V. Heinemann, D. Laessig, D. Nagel, D. Seidel, P. Stieber
Journal: Journal of Clinical Oncology (2009)

e12015 Background: Kinetics of CA 15–3 and CEA have a high specificity in the early detection (= asymptomatic patients) of metastatic breast cancer disease. However, this high specificity is associated with a lack of sensitivity (false-negative results). To decrease the number of false negative (FN) patients, the additional diagnostic potential of CA 125 kinetics was evaluated. Methods: We analysed 1,011 follow-up samples of 95 patients. Forty-seven of these patients showed metastatic recurrence during follow-up. Based on analyses, published previously, a reproducible increase of CA 125, CA 15–3, or CEA ≥100% based on the individual baseline value of each patient was selected as a reliable indicator for metastatic disease. Results: None of the 48 patients with NED had a reproducible increase of either CEA, CA 15–3, or CA125, i.e., all three tumor markers reached a specificity of 100%. At the time of first metastatic disease, the overall sensitivity was 29.8% for CA 125, 44.7% for CA 15–3, and 21.3% for CEA. In 7 patients (14.9%) only CA 125, in 14 patients (29.8%) only CA 15–3 and in 6 patients (12.8%) only CEA increased. In 8 patients (17.0%) more than one marker increased. The sensitivity of the CA 15–3/CEA combination was 59.6% (95%-CI: 45.5%-73.6%). With the additional use of CA 125, the sensitivity could be increased by 14.9% to 74.5% (95%-CI: 62.0–86.9%). The sensitivity of the marker combination was 66.6% for metastases in one site (n = 33) and 100% for metastases in more than one site (n = 14). Conclusions: This retrospective analysis indicates that CA 125 increased the sensitivity of the CA 15–3/CEA combination by 14.9% without loss of specificity. The combined use of CA15–3/CEA/CA125 may therefore be helpful for early detection of metastatic disease. The usefulness of this approach is presently verified in a prospective trial. [Table: see text]
Assessment of pathological complete response (pCR) to neoadjuvant dose-dense chemotherapy in HER2+ patients with locally advanced breast cancer (LABC) treated with trastuzumab (T) compared with HER2+ and HER2- patients treated without T
Authors: A. Sanchez-Muñoz, A. M. García-Tapiador, R. Dueñas-García, A. Jaén-Morago, E. Martínez-Ortega, M. Fernández-Navarro, C. de la Torre-Cabrera, B. Dueñas, F. Morales, P. Sánchez-Rovira
Journal: Journal of Clinical Oncology (2007)

11057 Purpose: To identify Her2+expression as predictive factor for pCR to T in pts with LABC treated with neoadjuvant chemotherapy. Methods: A total of 127 newly diagnosed stage II-III, including inflammatory tumors, breast cancer pts were reviewed. Median age was 47,7 (r 26,4 - 73,6). Median tumor size was 5 cm (1–10). 57 (44,8%) were T2, 33 (26%) T3 and 37 (29,2%) T4 (25 of them inflammatory). 59 (46,5%) pts were clinically lymph node positive before treatment. 50 pts (39,4%) were hormonal receptor negative, and 38 (30,4%) Her2+. The pts received one of the 2 chemotherapy regimens every 2 weeks with prophylactic growth factors support: A) epirubicin 90 mg/m 2 -cyclophophamide 600 mg/m 2 d1 for 3 cycles, followed by a second sequence with paclitaxel (P) 150 mg/m 2 - gemcitabine (G) 2500 mg/m 2 d1 ± T 2mg/kg/wk according to status Her2 (n= 73); B) adriamicin 40mg/m 2 d1 plus P 150mg/m 2 -G 2000 mg/m 2 d2 for 6 cycles (n=54). Subsequently pats underwent surgery and radiotherapy and/or adjuvant hormonal therapy according to institutional practice. Results: 43 (33,9 %) pts achieved a pCR (absence of invasive tumor in the breast). The pts were classified in two groups to analyze the influence of the treatment with T on pCR: (1) Her2+ pats treated with T (20 pts): pCR 50%; (2) The rest of the pts, treated only with chemotherapy (107 pts: 18 Her2+ and 89 Her2- ): pCR 32% (p=0.068). Breast-conserving surgery was performed in 77 pts (60,6%). Conclusions: Both dose dense chemotherapy regimens were highly effective in terms of pCR. Although there were not a significative correlation of Her2+ status and trastuzumab therapy with pCR, probably due to the small number of pts, a favorable tendency was seen in the group of Her2+ tumors treated with T. At the meeting, analysis of the correlation of pCR with progression free survival will be presented. No significant financial relationships to disclose.
Abstract 1384: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, reverses the HIF-1α-mediated increase in cancer stem cells caused by bevacizumab in a preclinical model of triple-negative breast cancer
Authors: Sarah J. Conley, Trenton L. Baker, Joseph P. Burnet, Rebecca L. Thiesen, Douglas Lazarus, Christian G. Peters, Shawn G. Clouthier, Scott Eliasof, Max S. Wicha
Journal: Cancer Research (2015)

Abstract Antiangiogenic agents are designed to impede the development of new tumor blood vessels, thereby starving tumors of oxygen and nutrients to ultimately block tumor growth. Despite advances made in developing antiangiogenic therapies, clinical and preclinical data suggest that these drugs have limited efficacy in breast cancer patients. Tumors inevitably develop resistance to antiangiogenic agents and patients frequently fail to demonstrate significantly better overall survival. Acquired resistance to antiangiogenic agents has been attributed in part to the induction of intra-tumoral hypoxia and the concomitant stabilization of hypoxia-inducible factor 1α (HIF-1α), a transcription factor that promotes tumor angiogenesis, invasion, metastasis, and cancer stem cell (CSC) self-renewal. In this preclinical model, we demonstrate that CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin (CPT), can reverse the stimulatory effects of hypoxia on the CSC population in an orthotopic triple-negative xenograft model. The payload, camptothecin, a topoisomerase 1 inhibitor, inhibits HIF-1α protein accumulation at concentrations below those that were cytotoxic to tumor cells, and inhibits hypoxia-mediated CSC induction at these low concentrations in vitro. In an orthotopic triple-negative breast cancer model, CRLX101 is synergistic with bevacizumab. Tumor reimplantation experiments confirm that the combination therapy effectively targets both the bulk tumor cell and CSC populations. Results generated from these preclinical studies support the clinical research of combining antiangiogenic agents with CRLX101 to increase patient survival. CRLX101 is currently in phase 2 clinical trials in combination with bevacizumab in both recurrent ovarian cancer and metastatic renal cell carcinoma. Citation Format: Sarah J. Conley, Trenton L. Baker, Joseph P. Burnet, Rebecca L. Thiesen, Douglas Lazarus, Christian G. Peters, Shawn G. Clouthier, Scott Eliasof, Max S. Wicha. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, reverses the HIF-1α-mediated increase in cancer stem cells caused by bevacizumab in a preclinical model of triple-negative breast cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1384. doi:10.1158/1538-7445.AM2015-1384
Bringing person-centered care to practice with CCO’s guideline for person-centred care in adult oncology services.
Authors: Lesley Moody, Brett Nicholls, Hannah Shamji, Neil Johnson, Caroline Zwaal, Christian Stevens, Rhonel Biddy, Carly Griffin, Gail Laroque, Hans Messersmith, Simron Singh
Journal: Journal of Clinical Oncology (2016)

65 Background: CCO ensures quality cancer care for 16 million residents in Ontario. CCO has identified person-centered care (PCC) as a top strategy in driving the quality agenda. CCO, in collaboration with the Program in Evidence-Based Care, developed a PCC Guideline to set the standard of care for people experiencing cancer in Ontario. A PCC video was developed as a tool for translating this knowledge to support healthcare providers to integrate Guideline recommendations into their practice. Methods: A Guideline Working Group (GWG), including patients and health care providers, conducted a literature review and assessed the quality, relevance and utility of available evidence. An Expert Panel reviewed the decisions of the GWG and an External Review was conducted to validate the final guideline. The PCC video was developed as a tool for knowledge translation by defining fundamental concepts of PCC with the objective of promoting uptake of the guideline. A 4-question survey based on the Kirkpatrick Model was embedded to evaluate the video’s effectiveness. Results: Of 110 articles, only one guideline was found and was therefore reviewed exclusively. The GWG reviewed 68 recommendations, modifying 48, accepting 13 and rejecting 4; for a final set of 65 recommendations. External Review returned 73 responses. A total of 196 health care providers, 134 administrators, 53 patients and 103 others stakeholders participated in the video survey. The results in the table below compare the educational state of PCC before and after the video. Conclusions: CCO has adapted and endorsed 65 recommendations to create a PCC Guideline for adult oncology in Ontario. The results of the video showed that baseline PCC knowledge is poor, and that the PCC Video initiated significant (p = 0.972) growth in this knowledge. Anecdotal evidence also suggests that the video positively affected health care provider's confidence in adopting PCC. Future work is required to promote uptake and utilization of PCC Guideline at system-level. [Table: see text]
P0427 : Platelet-derived growth factor-D intensifies fibrogenesis through upregulation of TIMP-1 and signaling via both platelet-derived growth factor receptor type alpha and beta
Authors: E. Borkham-Kamphorst, S.K. Meurer, E. Van de Leur, U. Haas, L. Tihaa, R. Weiskirchen
Journal: Journal of Hepatology (2015)
A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.
Authors: David A. Rizzieri, Eric Feldman, Joseph O. Moore, Gail J. Roboz, John F. DiPersio, Nashat Gabrail, Wendy Stock, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, Francis Giles
Journal: Blood (2005)
GW26-e2301 The CHADS 2 and CHA 2 DS 2 -VASc scores for predicting ischemic stroke amongst Asian patients with atrial fibrillation: A systemic review and meta-analysis
Authors: Qinmei Xiong, Sisi Chen, Keitaro Senoo, Marco Proietti, Kui Hong, Gregory YH Lip
Journal: Journal of the American College of Cardiology (2015)
GW26-e0208 Naturally occurring multiple-modified low density lipoprotein (LDL)
Authors: Alexander N. Orekhov, Natalia V. Elizova, Alexandra A. Melnichenko, Vasily P. Karagodin, Veronika A. Myasoedova, Andrey V. Zhelankin, Sergey S. Trubinov, Varvara A. Orekhova, Vasily V. Sinyov, Valeria A. Barinova, Anastasia V. Ryzhkova, Yuri V. Bobryshev, Igor A. Sobenin
Journal: Journal of the American College of Cardiology (2015)